Find similar products:
The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on 0800 198 5000. The product code(s) for this leaflet is: PLGB 53095/0029.
Isentress 25 mg and 100 mg Chewable Tablets
Isentress® 25 mg chewable tablets
Isentress® 100 mg chewable tablets
raltegravir
If you are the parent of a child taking Isentress, please read this information carefully with your child.
1. What Isentress is and what it is used for
2. What you need to know before you take Isentress
3. How to take Isentress
4. Possible side effects
5. How to store Isentress
6. Contents of the pack and other information
Isentress contains the active substance raltegravir. Isentress is an antiviral medicine that works against the Human Immunodeficiency Virus (HIV). This is the virus that causes Acquired Immune Deficiency Syndrome (AIDS).
The virus produces an enzyme called HIV integrase. This helps the virus to multiply in the cells in your body. Isentress stops this enzyme from working. When used with other medicines, Isentress may reduce the amount of HIV in your blood (this is called your "viral load") and increase your CD4-cell count (a type of white blood cells that plays an important role in maintaining a healthy immune system to help fight infection). Reducing the amount of HIV in the blood may improve the functioning of your immune system. This means your body may fight infection better.
Isentress is used to treat those who are infected by HIV. Your doctor has prescribed Isentress to help control your HIV infection.
Talk to your doctor, pharmacist or nurse before taking Isentress.
Remember that Isentress is not a cure for HIV infection. This means that you may keep getting infections or other illnesses associated with HIV. You should keep seeing your doctor regularly while taking this medicine.
Mental health problems
Tell your doctor if you have a history of depression or psychiatric illness. Depression, including suicidal thoughts and behaviours, has been reported in some patients taking this medicine, particularly in patients with a prior history of depression or psychiatric illness.
Bone problems
Some patients taking combination anti-retroviral therapy may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone). The length of combination anti-retroviral therapy, corticosteroid use, alcohol consumption, severe reduction of the activity of the immune system, higher body mass index, among others, may be some of the many risk factors for developing this disease. Signs of osteonecrosis are joint stiffness, aches and pains (especially of the hip, knee and shoulder) and difficulty in movement. If you notice any of these symptoms, please inform your doctor.
Liver problems
Tell your doctor, pharmacist or nurse if you have had problems with your liver before, including hepatitis B or C. Your doctor may evaluate how severe your liver disease is before deciding if you can take this medicine.
Infections
Tell your doctor, pharmacist or nurse immediately if you notice any symptoms of infection, such as fever, and/or feeling unwell. In some patients with advanced HIV infection and a history of opportunistic infection, signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started. It is believed that these symptoms are due to an improvement in the body’s immune response, enabling the body to fight infections that may have been present with no obvious symptoms.
In addition to the opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you start taking medicines for the treatment of your HIV infection. Autoimmune disorders may occur many months after the start of treatment. If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness beginning in the hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity, please inform your doctor immediately to seek necessary treatment.
Muscle problems
Contact your doctor, pharmacist or nurse immediately if you experience unexplained muscle pain, tenderness, or weakness while taking this medicine.
Skin problems
Contact your doctor promptly if you develop a rash. Severe and life-threatening skin reactions and allergic reactions have been reported in some patients taking this medicine.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines with or without a prescription.
Isentress might interact with other medicines.
Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take:
See section 3.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Ask your doctor, pharmacist or nurse for advice before taking any medicine if you are pregnant or breast-feeding.
Do not operate machines, drive or cycle if you feel dizzy after taking this medicine.
Isentress 25 mg chewable tablet
This medicine contains fructose up to 0.54 mg in each tablet. Fructose may damage teeth.
This medicine contains sorbitol (E 420) up to 1.5 mg in each tablet.
This medicine contains up to 3.5 mg of sucrose in each 25 mg chewable tablet.
Sucrose may be harmful to the teeth.
If you have been told by your doctor that you have an intolerance to some sugars, talk to your doctor before taking this medicine.
This medicine contains up to 0.47 mg aspartame (E 951) in each 25 mg chewable tablet which is equivalent to up to 0.05 mg phenylalanine. Aspartame is a source of phenylalanine. It may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.
Isentress 100 mg chewable tablet
This medicine contains fructose up to 1.07 mg in each tablet. Fructose may damage teeth.
This medicine contains sorbitol (E 420) up to 2.9 mg in each tablet.
This medicine contains up to 7 mg of sucrose in each 100 mg chewable tablet.
Sucrose may be harmful to the teeth.
If you have been told by your doctor that you have an intolerance to some sugars, talk to your doctor before taking this medicine.
This medicine contains up to 0.93 mg aspartame (E 951) in each 100 mg chewable tablet which is equivalent to up to 0.10 mg phenylalanine. Aspartame is a source of phenylalanine. It may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.
Always take this medicine exactly as your doctor, pharmacist or nurse has told you. You should check with your doctor, pharmacist or nurse if you are not sure. Isentress must be used in combination with other medicines for HIV.
The 100 mg chewable tablet can be split into equal halves. However, breaking the tablets should be avoided whenever possible.
Dose for children of 2 through 11 years of age
The doctor will work out the right dose of the chewable tablet based on the age and weight of the child. This dose must not exceed 300 mg twice a day. The doctor will tell you how many chewable tablets the child must take.
Isentress is also available in a 400 mg tablet, a 600 mg tablet and in granules for oral suspension. Do not switch between the chewable tablet, granules for oral suspension, 600 mg tablet or 400 mg tablet without first talking with your doctor, pharmacist or nurse.
Children should keep scheduled doctor’s visits because their Isentress dosage should be adjusted as they get older, grow or gain weight. Their doctor may also want to prescribe the 400 mg tablet when they are able to swallow a tablet.
You can take this medicine with or without food or drink.
Do not take more tablets than the doctor recommends. If you do take too many tablets, contact your doctor.
It is important that you take Isentress exactly as your doctor has instructed. Do not change the dose or stop taking this medicine without first talking with your doctor, pharmacist or nurse. Do not stop taking it because:
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects – these are uncommon (may affect up to 1 in 100 people)
See a doctor immediately, if you notice any of the following:
See a doctor immediately, if you notice any of the side effects above.
Common: the following may affect up to 1 in 10 people
Uncommon: the following may affect up to 1 in 100 people
Additional side effects in children and adolescents
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
The active substance is raltegravir.
25 mg chewable tablets:
Each chewable tablet contains 25 mg of raltegravir (as potassium).
The other ingredients are: hydroxypropyl cellulose, sucralose, saccharin sodium, sodium citrate dihydrate, mannitol (E 421), yellow iron oxide, monoammonium glycyrrhizinate, sorbitol (E 420), fructose, natural and artificial flavours (orange, banana, and masking), aspartame (E 951), sucrose, crospovidone Type A, magnesium stearate, sodium stearyl fumarate, ethylcellulose 20 cP, ammonium hydroxide, medium chain triglycerides, oleic acid, hypromellose 2910/6cP and macrogol/PEG 400.
100 mg chewable tablets:
Each chewable tablet contains 100 mg of raltegravir (as potassium).
The other ingredients are: hydroxypropyl cellulose, sucralose, saccharin sodium , sodium citrate dihydrate, mannitol (E 421), red iron oxide, yellow iron oxide, monoammonium glycyrrhizinate, sorbitol (E 420), fructose, natural and artificial flavours (orange, banana, and masking), aspartame (E 951), sucrose, crospovidone Type A, magnesium stearate, sodium stearyl fumarate, ethylcellulose 20 cP, ammonium hydroxide, medium chain triglycerides, oleic acid, hypromellose 2910/6cP, and macrogol/PEG 400.
Isentress 25 mg chewable tablets:
The orange-banana flavoured chewable tablet is round and pale yellow, marked with the MSD corporate logo on one side and “473” on the other side.
One pack size is available: 1 bottle with 60 tablets. The bottle contains desiccant.
Isentress 100 mg chewable tablets:
The orange-banana flavoured chewable tablet is oval-shaped, pale orange coloured, scored on both sides with the MSD corporate logo and "477" on one side and without inscription on the other side.
One pack size is available: 1 bottle with 60 tablets. The bottle contains desiccant.
Marketing Authorisation Holder:
Manufacturer:
For any information about this medicine, please contact:
This leaflet was last revised in November 2022
© 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
PIL.IST.25mg+100mg.22.GB.8298.IB-013.RCN024947